|
1
|
Mody K and Abou-Alfa GK: Systemic therapy
for advanced hepatocellular carcinoma in an evolving landscape.
Curr Treat Options Oncol. 20:3–12. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ramia E, Chiaravalli AM, Bou Nasser Eddine
F, Tedeschi A, Sessa F, Accolla RS and Forlani G: CIITA-related
block of HLA class II expression, upregulation of HLA class I, and
heterogeneous expression of immune checkpoints in hepatocarcinomas:
Implications for new therapeutic approaches. Oncoimmunology.
8:3–13. 2019. View Article : Google Scholar
|
|
3
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Liu W, Li X, Zheng W, Yao R and Zheng J:
Preoperative evaluation of the degree of liver fibrosis based on
matter-element analysis using serological indicators in patients
with hepatocellular carcinoma. Biosci Trends. 13:70–76. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Raoul JL, Gilabert M and Adhoute X: To
TACE or not to TACE? Lessons from a negative trial. Lancet
Gastroenterol Hepatol. 2:541–543. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Voutsadakis IA: PD-1 inhibitors
monotherapy in hepatocellular carcinoma: Meta-analysis and
systematic review. Hepatobiliary Pancreat Diseases Int. 9:261–272.
2019.
|
|
8
|
Greten TF, Wang XW and Korangy F: Current
concepts of immune based treatments for patients with HCC: From
basic science to novel treatment approaches. Gut. 64:842–848. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kudo M: Immune checkpoint inhibition in
hepatocellular carcinoma: Basics and ongoing clinical trials.
Oncology. 92 (Suppl 1):S50–S62. 2017. View Article : Google Scholar
|
|
10
|
Kudo M: Limited impact of Anti-PD-1/PD-L1
monotherapy for hepatocellular carcinoma. Liver Cancer. 9:629–639.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Topalian SL, Drake CG and Pardoll DM:
Immune checkpoint blockade: A common denominator approach to cancer
therapy. Cancer Cell. 27:450–461. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
National Comprehensive Cancer Network, .
NCCN Clinical Practice Guidelines in Oncology. Hepatobiliary
Cancers. Version 2.2019. NCCN; 2019
|
|
13
|
Pardoll DM: The blockade of immune
checkpoints in cancer immunotherapy. Nat Rev Cancer. 12:252–264.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ,
Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al:
Safety and activity of anti-PD-L1 antibody in patients with
advanced cancer. N Engl J Med. 366:2455–2465. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
El-Khoueiry AB, Sangro B, Yau T, Crocenzi
TS, Kudo M, Hsu C, Kim TY, Choo SP, Trojan J, Welling TH Rd, et al:
Nivolumab in patients with advanced hepatocellular carcinoma
(CheckMate 040): An open-label, non-comparative, phase 1/2 dose
escalation and expansion trial. Lancet. 389:2492–2502. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sangro B, Melero I, Yau T, et al:
Nivolumab in sorafenib-naive and -experienced patients with
advanced hepatocellular carcinoma (HCC): Survival, hepatic safety,
and biomarker assessments in CheckMate 040. Hepatology. 66:1–148.
2017.PubMed/NCBI
|
|
17
|
El-Khoueiry AB, Melerol I, Yau TC,
Crocenzi TS, Kudo M, Hsu C, Choo S, Trojan J, Welling T, Meyer T,
et al: Impact of antitumor activity on survival outcomes, and
nonconventional benefit, with nivolumab (NIVO) in patients with
advanced hepatocellular carcinoma (aHCC): Subanalyses of
CheckMate-040. J Clin Oncol. 36:4752018.https://meetinglibrary.asco.org/record/156075/abstract
View Article : Google Scholar
|
|
18
|
Yau T, Park JW, Finn RS, Cheng AL,
Mathurin P, Edeline J, Kudo M, Han KH, Harding JJ, Merle P, et al:
LBA38_PR-CheckMate 459: A randomized, multi-center phase III study
of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment
in patients (pts) with advanced hepatocellular carcinoma (aHCC).
Ann Oncol. 30:v874–v875. 2019. View Article : Google Scholar
|
|
19
|
Lee HW, Cho KJ and Park JY: Current status
and future direction of immunotherapy in hepatocellular carcinoma:
What do the data suggest? Immune Netw. 20:e112020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yau T, Kang YK, Kim TY, El-Khoueiry AB,
Santoro A, Sangro B, Melero I, Kudo M, Hou MM, Matilla A, et al:
Efficacy and safety of Nivolumab Plus Ipilimumab in patients with
advanced hepatocellular carcinoma previously treated with
Sorafenib: The CheckMate 040 randomized clinical trial. JAMA Oncol.
6:e2045642020. View Article : Google Scholar
|
|
21
|
Lee CH, Lee YB, Kim MA, Jang H, Oh H, Kim
SW, Cho EJ, Lee KH, Lee JH, Yu SJ, et al: Effectiveness of
nivolumab versus regorafenib in hepatocellular carcinoma patients
who failed sorafenib treatment. Clin Mol Hepatol. 26:328–339. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Choi WM, Choi J, Lee D, Shim JH, Lim YS,
Lee HC, Chung YH, Lee YS, Park SR, Ryu MH, et al: Regorafenib
versus nivolumab after sorafenib failure: Real-world data in
patients with hepatocellular carcinoma. Hepatol Commun.
4:1073–1086. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kudo M: Pembrolizumab for the treatment of
hepatocellular carcinoma. Liver Cancer. 8:143–154. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhu AX, Finn RS, Edeline J, Cattan S,
Ogasawara S, Palmer D, Verslype C, Zagonel V, Fartoux L, Vogel A,
et al: Pembrolizumab in patients with advanced hepatocellular
carcinoma previously treated with sorafenib (KEYNOTE-224): A
non-randomised, open-label phase 2 trial. Lancet Oncol. 19:940–952.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Finn R, Chan SL, Zhu AX, Knox J, Cheng AL,
Siegel A, Bautista O, Watson PA and Kudo M: Pembrolizumab vs best
supportive care for second-line advanced hepatocellular carcinoma:
Randomized, phase 3 KEYNOTE-240 study. Ann Oncol. 27 (Suppl
6):vi207–vi242. 2016. View Article : Google Scholar
|
|
26
|
Finn RS, Ryoo BY, Merle P, Kudo M,
Bouattour M, Lim HY, Breder V, Edeline J, Chao Y, Ogasawara S, et
al: Pembrolizumab as second-line therapy in patients with advanced
hepatocellular carcinoma in KEYNOTE-240: A randomized, doubleblind,
phase III trial. J Clin Oncol. 38:193–202. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ikeda M, Sung MW, Kudo M, Baron AD, Finn
RS, Kaneko S, Zhu A, Kubota T, Kralijevic S, Kralijevic H, et al:
abstract CT061: A phase Ib trial of lenvatinib (Len) plus
pembrolizumab (Pembro) in unresectable hepatocellular carcinoma
(uHCC): Updated results. Proceedings: AACR Annual Meeting; Atlanta,
GA: 2019, View Article : Google Scholar
|
|
28
|
Llovet JM, Kudo M, Cheng AL, Finn RS,
Galle PR, Kaneko S, Meyer T, Qin S, Dutcus CE, Chen E, et al:
Lenvatinib (len) plus pembrolizumab (pembro) for the first-line
treatment of patients (pts) with advanced hepatocellular carcinoma
(HCC): Phase 3 LEAP-002 study. J Clin Oncol. 37 (Suppl):abstract
TPS4152. 2019. View Article : Google Scholar
|
|
29
|
Markham A: Atezolizumab: First global
approval. Drugs. 76:1227–1232. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
FDA, . FDA approves new, targeted
treatment for bladder cancer media release. 6–Jun;2016.http://www.fda.gov
|
|
31
|
Finn RS, Qin S, Ikeda M, Galle PR, Ducreux
M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, et al: Atezolizumab
plus Bevacizumab in unresectable hepatocellular carcinoma. N Engl J
Med. 382:1894–1905. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lee M, Ryoo BY, Hsu CH, Numata K, Stein S,
Verret W, Hack S, Spahn J, Liu B, Abdullah H, et al: Randomised
efficacy and safety results for atezolizumab (Atezo) + bevacizumab
(Bev) in patients (pts) with previously untreated, unresectable
hepatocellular carcinoma (HCC). Ann Oncol. 30:1112019.
|
|
33
|
Kudo M, Motomura K, Wada Y, Inaba Y,
Sakamoto Y, Kurosaki M, Umeyama Y, Kamei Y, Yoshimitsu J, Fujii Y,
et al: First-line avelumab + axitinib in patients with advanced
hepatocellular carcinoma: Results from a phase 1b trial (VEGF Liver
100). J Clin Oncol. 37:40722019. View Article : Google Scholar
|
|
34
|
El Dika I, Khalil DN and Abou-Alfa GK:
Immune checkpoint inhibitors for hepatocellular carcinoma. Cancer.
125:3312–3319. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yang H, Shen K, Zhu C, Li Q, Zhao Y and Ma
X: Safety and efficacy of durvalumab (MEDI4736) in various solid
tumors. Drug Des Devel Ther. 12:2085–2096. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kelley RK, Abou-Alfa GK, Bendell JC, Kim
TY, Borad MJ, Yong WP, Morse M, Kang YK, Rebelatto M, Makowsky M,
et al: Phase I/II study of durvalumab and tremelimumab in patients
with unresectable hepatocellular carcinoma (HCC): Phase I safety
and efficacy analyses. J Clin Oncol. 35:40732017. View Article : Google Scholar
|
|
37
|
Floudas CS, Xie C, Brar G, Morelli MP,
Fioravanti S, Walker M, Mabry-Hrones D, Wood BJ, Levy EB, Venkatesh
P, et al: Combined immune checkpoint inhibition (ICI) with
tremelimumab and durvalumab in patients with advanced
hepatocellular carcinoma (HCC) or biliary tract carcinomas (BTC). J
Clin Oncol. 37:3362019. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Bang YJ, Golan T, Lin CC, Dahan L, Fu S,
Moreno V, Geva R, Reck M, Wasserstrom HA, Mi G, et al: Ramucirumab
(Ram) and durvalumab (Durva) treatment of metastatic non-small cell
lung cancer (NSCLC), gastric/gastroesophageal junction (G/GEJ)
adenocarcinoma, and hepatocellular carcinoma (HCC) following
progression on systemic treatment(s). J Clin Oncol. 37:25282019.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Fanciulli G, Di Molfetta S, Dotto A,
Florio T, Feola T, Rubino M, de Cicco F, Colao A and Faggiano A;
Nike Group, : Emerging therapies in pheochromocytoma and
paraganglioma: Immune checkpoint inhibitors in the starting blocks.
J Clin Med. 10:882020. View Article : Google Scholar
|
|
40
|
Pishvaian MJ, Weiss GJ, Falchook GS, Yee
N, Gil-Martin M, Shahda S, Moreno V, Brana I, Crittenden M,
Formenti S, et al: Cemiplimab, a human monoclonal anti-PD-1, in
patients with advanced or metastatic hepatocellular carcinoma
(HCC): Data from an expansion cohort in a phase 1 study. Ann Oncol.
29:3272018. View Article : Google Scholar
|
|
41
|
Liu X and Qin S: Immune checkpoint
inhibitors in hepatocellular carcinoma: Opportunities and
challenges. Oncologist. 24 (Suppl 1):S3–S10. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Keam SJ: Toripalimab: First global
approval. Drugs. 79:573–578. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Liu L and Qin S: Research status and
progress of molecular targeted drugs and immunocheckpoint
inhibitors in the treatment of advanced HCC. J Clin Oncol.
24:839–849. 2019.
|
|
44
|
Wu S: Progress of clinical study on
treatment of advanced hepatocellular carcinoma with immune
checkpoint inhibitors. Chinese J Oncol. 28:780–785. 2019.
|
|
45
|
Lee A and Keam SJ: Tislelizumab: First
approval. Drugs. 80:617–624. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Desai J, Deva S, Lee JS, Lin CC, Yen CJ,
Chao Y, Keam B, Jameson M, Hou MM, Kang YK, et al: Phase IA/IB
study of single-agent tislelizumab, an investigational anti-PD-1
antibody, in solid tumors. J Immunother Cancer. 8:e0004532020.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Sangro B, Melero I, Wadhawan S, Finn RS,
Abou-Alfa GK, Cheng AL, Yau T, Furuse J, Park JW, Boyd Z, et al:
Association of inflammatory biomarkers with clinical outcomes in
nivolumab-treated patients with advanced hepatocellular carcinoma.
J Hepatol. 73:1460–1469. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Liu L and Qin S: Research status and
progress of molecular targeted drugs and immunocheckpoint
inhibitors in the treatment of advanced HCC. J Clin Oncol.
24:839–849. 2019.
|
|
49
|
Polasky C, Steffen A, Loyal K, Lange C,
Bruchhage KL and Pries R: Redistribution of monocyte subsets in
obstructive sleep apnea syndrome patients leads to an imbalanced
PD-1/PD-L1 cross-talk with CD4/CD8 T cells. J Immunol. 206:51–58.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Zhang H, Li XX, Yang Y, Zhang Y, Wang HY
and Zheng XFS: Significance and mechanism of androgen receptor
overexpression and androgen receptor/mechanistic target of
rapamycin cross-talk in hepatocellular carcinoma. Hepatology.
67:2271–2286. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Bruix J, Cheng AL, Meinhardt G, Nakajima
K, De Sanctis Y and Llovet J: Prognostic factors and predictors of
sorafenib benefit in patients with hepatocellular carcinoma:
Analysis of two phase III studies. J Hepatol. 67:999–1008. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Pedoeem A, Azoulay-Alfaguter I, Strazza M,
Silverman GJ and Mor A: Programmed death-1 pathway in cancer and
autoimmunity. Clin Immunol. 153:145–152. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Akbay EA, Koyama S, Carretero J, Altabef
A, Tchaicha JH, Christensen CL, Mikse OR, Cherniack AD, Beauchamp
EM, Pugh TJ, et al: Activation of the PD-1 pathway contributes to
immune escape in EGFR-driven lung tumors. Cancer Discov.
3:1355–1363. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Azuma K, Ota K, Kawahara A, Hattori S,
Iwama E, Harada T, Matsumoto K, Takayama K, Takamori S, Kage M, et
al: Association of PD-L1 40 overexpression with activating EGFR
mutations in surgically resected nonsmall-cell lung cancer. Ann
Oncol. 25:1935–1940. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Chen N, Fang W, Zhan J, Hong S, Tang Y,
Kang S, Zhang Y, He X, Zhou T, Qin T, et al: Upregulation of PD-L1
by EGFR activation mediates the immune Escape in EGFR-Driven NSCLC:
Implication for optional immune targeted therapy for NSCLC patients
with EGFR mutation. J Thorac Oncol. 10:910–923. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Sarfaty M, Leshno M, Gordon N, Moore A,
Neiman V, Rosenbaum E and Goldstein DA: Cost effectiveness of
nivolumab in advanced renal cell carcinoma. Eur Urol. 73:628–634.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Im JS, Herrmann AC, Bernatchez C, Haymaker
C, Molldrem JJ, Hong WK and Perez-Soler R: Immune-modulation by
epidermal growth factor receptor inhibitors: Implication on
anti-tumor immunity in lung cancer. PLoS One. 11:e01600042016.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Weber JS, Kahler KC and Hauschild A:
Management of immune-related adverse events and kinetics of
response with ipilimumab. J Clin Oncol. 30:2691–2697. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Topalian SL, Sznol M, McDermott DF, Kluger
HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB,
Powderly JD, et al: Survival, durable tumor remission, and
long-term safety in patients with advanced melanoma receiving
nivolumab. J Clin Oncol. 32:1020–1030. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Wang Y, Zhou S, Yang F, Qi X, Wang X, Guan
X, Shen C, Duma N, Vera Aguilera J, Chintakuntlawar A, et al:
Treatment-related adverse events of PD-1 and PD-L1 inhibitors in
clinical trials: A systematic review and meta-analysis. JAMA Oncol.
5:1008–1019. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Baxi S, Yang A, Gennarelli RL, Khan N,
Wang Z, Boyce L and Korenstein D: Immune-related adverse events for
anti-PD-1 and anti-PD-L1 drugs: Systematic review and
meta-analysis. BMJ. 360:k7932018. View Article : Google Scholar : PubMed/NCBI
|
